临床试验登记· Tongji Hospital · ClinicalTrials.gov·· 10 小时前评分29
HER2表达肌层浸润性膀胱癌：Trastuzumab Rezetecan联合Adebrelimab及同步放疗的应答指导保膀胱2期试验
Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer
导读
NCT07865611是同济医院登记的多中心开放标签2期试验，计划入组70例HER2表达肌层浸润性膀胱癌患者，评估Trastuzumab Rezetecan联合Adebrelimab及同步膀胱放疗的应答指导保膀胱策略。放疗后8周通过活检评估疗效，病理分期T1及以下可继续保膀胱，高于T1则推荐根治性膀胱切除。主要终点为主要病理缓解率。
来源：临床试验登记 · clinicaltrials.gov